- Conditions
- Triple Negative Breast Cancer, Diffuse Large B Cell Lymphoma, Follicular Lymphoma, Lymphoma, Non-Hodgkin, Mantle Cell Lymphoma, Bladder Cancer, Uveal Melanoma, Recurrent, Cervix Cancer, Carcinoma in Situ, Head and Neck Squamous Cell Carcinoma, Skin Cancer, Metastatic Cancer, Tumor, Solid, Tumor Recurrence
- Interventions
- ONM-501, Cemiplimab
- Drug
- Lead sponsor
- OncoNano Medicine, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 168 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 9
- States / cities
- Los Angeles, California • Tamarac, Florida • Canton, Ohio + 5 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 24
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- CD20 Positive, Recurrent Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma
- Interventions
- Carboplatin, Etoposide, Ibrutinib, Ifosfamide, Laboratory Biomarker Analysis, Pharmacological Study, Rituximab
- Drug · Other · Biological
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2017
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Diffuse Large B-cell Lymphoma
- Interventions
- Tafasitamab
- Drug
- Lead sponsor
- Incyte Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 102 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 26
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Orange, California + 22 more
- Conditions
- Hodgkin's Disease, Lymphoma
- Interventions
- rituximab, cyclophosphamide, etoposide, prednisone, vorinostat and QOL questionnaire, peg-filgrastim or filgrastim
- Drug
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 60 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2017
- U.S. locations
- 5
- States / cities
- Basking Ridge, New Jersey • Commack, New York • New York, New York + 1 more
- Conditions
- Acute Myeloid Leukemia, Multiple Myeloma, Diffuse Large B-cell Lymphoma
- Interventions
- MEDI7247
- Drug
- Lead sponsor
- MedImmune LLC
- Industry
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 67 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 10
- States / cities
- Los Angeles, California • Denver, Colorado • Atlanta, Georgia + 7 more
- Conditions
- DLBCL, Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma, DLBCL Arising From Follicular Lymphoma
- Interventions
- E7777, Fludarabine, Cyclophosphamide, Tisagenlecleucel, Axicabtagene Ciloleucel, Lisocabtagene Maraleucel Intravenous Suspension
- Drug
- Lead sponsor
- Masonic Cancer Center, University of Minnesota
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Non-GCB/ABC Diffuse Large B-Cell Lymphoma, With and Without MyD88 and/or CD79B Mutations
- Interventions
- Mivavotinib
- Drug
- Lead sponsor
- Calithera Biosciences, Inc
- Industry
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 7
- States / cities
- Evanston, Illinois • Detroit, Michigan • Cleveland, Ohio + 4 more
- Conditions
- Solid Tumors and Hematologic Malignancy
- Interventions
- INCB054329 Monotherapy
- Drug
- Lead sponsor
- Incyte Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 69 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2018
- U.S. locations
- 12
- States / cities
- Los Angeles, California • San Francisco, California • Denver, Colorado + 8 more
- Conditions
- Refractory Aggressive B-cell Lymphomas, Refractory B-Cell Non-Hodgkin Lymphoma, Aggressive B-cell NHL, Diffuse Large B-cell Lymphoma (DLBCL), De Novo or Transformed Indolent B-cell Lymphoma, DLBCL, Nos Genetic Subtypes, T Cell/Histiocyte-rich Large B-cell Lymphoma, EBV-Positive DLBCL, Nos, Primary Mediastinal [Thymic] Large B-cell Lymphoma (PMBCL), High-Grade B-Cell Lymphoma, Nos, C-MYC/BCL6 Double-Hit High-Grade B-Cell Lymphoma, Grade 3b Follicular Lymphoma, C-MYC/BCL2 Double-Hit High-Grade B-Cell Lymphoma
- Interventions
- ACALABRUTINIB, LISOCABTAGENE MARALEUCEL, Lymphodepleting chemotherapy
- Drug
- Lead sponsor
- Patrick C. Johnson, MD
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2029
- U.S. locations
- 2
- States / cities
- Boston, Massachusetts
- Conditions
- Diffuse Large B-Cell Lymphoma, B-cell Non-Hodgkin's Lymphoma
- Interventions
- Debio 1562, Rituximab
- Drug
- Lead sponsor
- Debiopharm International SA
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2021
- U.S. locations
- 9
- States / cities
- Birmingham, Alabama • Urbana, Illinois • Minneapolis, Minnesota + 6 more
- Conditions
- Diffuse Large B-cell Lymphoma
- Interventions
- dasatinib
- Drug
- Lead sponsor
- Weill Medical College of Cornell University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2011
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Non-Hodgkin's Lymphoma
- Interventions
- Obinutuzumab, Rituximab, Polatuzumab Vedotin, Venetoclax
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 133 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2022
- U.S. locations
- 10
- States / cities
- Tucson, Arizona • New Haven, Connecticut • Pembroke, Florida + 7 more
- Conditions
- Diffuse Large B-cell Lymphoma, High-Grade B-cell Lymphoma
- Interventions
- RO6870810, Venetoclax, Rituximab
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 39 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 4
- States / cities
- Duarte, California • Stanford, California • New York, New York + 1 more
- Conditions
- Advanced Solid Tumor, DLBCL
- Interventions
- RNK05047
- Drug
- Lead sponsor
- Ranok Therapeutics (Hangzhou) Co., Ltd.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 3
- States / cities
- Atlanta, Georgia • Louisville, Kentucky • New York, New York
- Conditions
- Relapsed/Refractory B-cell Lymphomas, Diffuse Large B-Cell Lymphoma (DLBCL), Follicular Lymphoma (FL), Chronic Lymphocytic Leukemia (CLL), Marginal Zone Lymphoma (MZL), Mantle Cell Lymphoma (MCL), Small Lymphocytic Lymphoma (SLL), Primary Mediastinal Large B Cell Lymphoma, Transformed Follicular Lymphoma, Waldenstrom Macroglobulinemia, Lymphoplasmacytic Lymphoma, Burkitt Lymphoma
- Interventions
- CLBR001 and SWI019
- Combination Product
- Lead sponsor
- Calibr, a division of Scripps Research
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 8
- States / cities
- Duarte, California • San Diego, California • Chicago, Illinois + 5 more
- Conditions
- Relapsed or Refractory Diffuse Large B Cell Lymphoma (DLBCL)
- Interventions
- Blinatumomab, Pembrolizumab
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 31 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2023
- U.S. locations
- 3
- States / cities
- La Jolla, California • Charleston, South Carolina • Greenville, South Carolina
- Conditions
- B-cell Non-Hodgkin Lymphoma (B-NHL)
- Interventions
- Odronextamab
- Drug
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 515 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2028
- U.S. locations
- 13
- States / cities
- Chicago, Illinois • Iowa City, Iowa • Louisville, Kentucky + 9 more
- Conditions
- Lymphoma
- Interventions
- rituximab, cyclophosphamide, doxorubicin hydrochloride, prednisone, vincristine sulfate, R-CHOP regimen, laboratory biomarker analysis, fludeoxyglucose F 18, selective external radiation therapy, yttrium Y 90 ibritumomab tiuxetan
- Biological · Drug · Other + 1 more
- Lead sponsor
- SWOG Cancer Research Network
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 159 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2023
- U.S. locations
- 240
- States / cities
- Anchorage, Alaska • Tucson, Arizona • Aurora, Colorado + 153 more
- Conditions
- Diffuse Large B-Cell Lymphoma, Follicular Lymphoma, Marginal Zone Lymphoma, Mantle Cell Lymphoma, Small Lymphocytic Lymphoma
- Interventions
- Ublituximab, Umbralisib, Bendamustine
- Biological · Drug
- Lead sponsor
- TG Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 710 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2022
- U.S. locations
- 111
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Chandler, Arizona + 97 more
- Conditions
- Diffuse Large B-Cell Lymphoma
- Interventions
- MEDI4736, tremelimumab, AZD9150
- Drug
- Lead sponsor
- MedImmune LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2019
- U.S. locations
- 8
- States / cities
- La Jolla, California • Baltimore, Maryland • Albuquerque, New Mexico + 5 more
- Conditions
- Lymphoma, Lymphoma, B-Cell, Diffuse Large B Cell Lymphoma, Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, High-grade B-cell Lymphoma
- Interventions
- Phased Variant Enrichment and Detection Sequencing (PhasED-seq), Standard of Care Treatment, De-escalated Treatment
- Device · Other
- Lead sponsor
- Hua-Jay J Cherng, MD
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2029
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- B-Cell Lymphoma, Non-Hodgkin Lymphoma
- Interventions
- Glofitamab, Obinutuzumab (G), Rituximab (R), Tocilizumab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, Polatuzumab vedotin
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 111 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2024
- U.S. locations
- 3
- States / cities
- Birmingham, Alabama • Charlotte, North Carolina • Philadelphia, Pennsylvania
- Conditions
- Diffuse Large B Cell Lymphoma, Relapsed Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma
- Interventions
- Copanlisib, Venetoclax
- Drug
- Lead sponsor
- Dana-Farber Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 3
- States / cities
- Duarte, California • Boston, Massachusetts • St Louis, Missouri
- Conditions
- Diffuse Large B-cell Lymphoma
- Interventions
- TAK-659
- Drug
- Lead sponsor
- Calithera Biosciences, Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 49 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 10
- States / cities
- Westwood, Kansas • Ann Arbor, Michigan • Buffalo, New York + 5 more